Jo Yang-hyun
Sungkyunkwan University · Medicine
About the Lab
Professor Jo Yang-hyun's research lab specializes in advanced cardiovascular critical care and interventional cardiology, with a primary focus on extracorporeal life support (ECLS) and extracorporeal cardiopulmonary resuscitation (ECPR) in patients with severe cardiac and pulmonary complications. The lab investigates innovative percutaneous and surgical interventions—such as percutaneous transseptal left atrial drainage and atrial septal defect closure with fenestrated patches—for managing life-threatening hemodynamic instability in patients with right heart failure, pulmonary hypertension, or massive pulmonary embolism. The team also explores predictive scoring systems for organ failure and long-term outcomes following heart transplantation on ECLS, aiming to optimize patient selection and postoperative management.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Prophylactic percutaneous transseptal left atrial (LA) drainage at ECMO initiation appeared to be associated with a lower early mortality rate and a higher likelihood of successful bridging to cardiac replacement therapy than therapeutic LHD to treat complications of left ventricular distension.
Extracorporeal cardiopulmonary resuscitation (ECPR) has been performed with increasing frequency worldwide to improve the low survival rate of conventional cardiopulmonary resuscitation (CCPR). Several studies have shown that among patients who experience in-hospital cardiac arrest, better survival outcomes and neurological outcomes can be expected after ECPR than after CCPR. However, studies have not clearly shown a short-term survival benefit of ECPR for patients who experience out-of-hospital
Our results suggest that the GPS as well as performance status, DM, and cortical thinning are associated with intravesical recurrence after RNU. Thus, more careful follow-up, coupled with postoperative intravesical therapy to avoid bladder recurrence, should be considered in these patients.
The aim of the study was to review our experience with atrial septal defect (ASD) closure with a fenestrated patch in patients with severe pulmonary hypertension. Between July 2004 and February 2009, 16 patients with isolated ASD underwent closure with a fenestrated patch. All patients had a secundum type ASD and severe pulmonary hypertension. Patients ranged in age from 6 to 57 years (mean ± SD, 34.9 ± 13.5 years). The follow-up period was 9 to 59 months (mean, 34.5 ± 13.1 months). The ranges o
We investigated the utility of comprehensive scoring systems for organ failure compared with the duration of extracorporeal life support (ECLS) in predicting survival after heart transplantation. From November 2004 to August 2013, 25 adult patients ultimately underwent heart transplantation while on ECLS. We did not include patients who were younger than 18 years old or patients with extracorporeal ventricular assist devices. Seven patients (28%) died within 1 year after transplantation. The are
Cardiac arrest caused by acute pulmonary embolism is associated with high patient mortality. We reviewed patients who had cardiac arrest caused by acute pulmonary embolism. Between January 2001 and September 2013, we identified 20 patients at our institution with a confirmative diagnosis of acute pulmonary thromboembolism and cardiac arrest. Percutaneous cardiopulmonary support (PCPS) and surgical embolectomy are the standard course of care for patients with shock or cardiac arrest caused by pul
Despite the rapid development of therapeutic modalities for metastatic renal cell carcinoma (mRCC) over the past decade to include a number of targeted antiangiogenic therapies and traditional immunotherapy, such as high-dose interleukin-2 and interferon-α, mRCC continues to be associated with poor prognosis. Currently, several novel immunotherapy agents, such as cancer vaccines, adoptive cell therapy, and checkpoint inhibitors, such as programmed cell death-1 (PD-1 present on T cells), one of i
Unfractionated heparin (UFH) is currently the standard anticoagulant used in extracorporeal life support (ECLS). However, severe thrombocytopenia occurs frequently during ECLS use and it may be difficult to determine whether this represents heparin-induced thrombocytopenia (HIT) or not. In this case, UFH cannot be continued. Because a confirmatory laboratory test requires time, argatroban is empirically used if HIT is suspected. However, many patients are not found to have HIT. In non-HIT patien
Research Areas
Dive deeper into Jo Yang-hyun's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.